Drugs / IZILENDUSTAT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03860896 | Apr → Dec 2019 | ulcerative colitis | Gossamer Bio, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04556383 | Oct 2020 → Jun 2022 | ulcerative colitis | GB004, Inc. | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IZILENDUSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3115298 ↗ |
| Known as | GB004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04556383 ↗ |
| Modality | Small molecule | “GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of...” PMID 35014040 ↗ Jan 2022 |
| Route | Oral | “GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of...” PMID 35014040 ↗ Jan 2022 |
| Target | HIF1A | “GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with protective roles at the epithelial layer of...” PMID 35014040 ↗ Jan 2022 |